Trial Profile
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Sep 2020 Results (n=272) of pooled analysis of three clinical studies ((B1371001or NCT00953758), (B1371002 or NCT01286467) and (B1371003 or NCT01546038)) assessing evaluation of the relationship of Glasdegib exposure and safety end points in patients with refractory solid tumors and hematologic malignancies, published in the Journal of Clinical Pharmacology.
- 25 Nov 2019 Results of a population pharmacokinetics analysis and data were pooled from three clinical glasdegib studies; (n=47 ; B1371001or NCT00953758), (n=23 ; B1371002 or NCT01286467) and (n=202 ; B1371003 or NCT01546038) were published in the Journal of Clinical Pharmacology
- 28 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.